XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Sales $ 15,901 $ 10,627
Costs, Expenses and Other    
Cost of sales 5,380 3,199
Selling, general and administrative 2,323 2,187
Research and development 2,576 2,412
Restructuring costs 53 297
Other (income) expense, net 708 (455)
Total Costs, Expenses and Other 11,040 7,640
Income from Continuing Operations Before Taxes 4,861 2,987
Taxes on Income from Continuing Operations 554 238
Net Income from Continuing Operations 4,307 2,749
Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 4
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,310 2,745
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 434
Net Income Attributable to Merck & Co., Inc. $ 4,310 $ 3,179
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:    
Income from Continuing Operations (in dollars per share) $ 1.70 $ 1.08
Income from Discontinued Operations (in dollars per share) 0 0.17
Net Income (in dollars per share) 1.70 1.26
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:    
Income from Continuing Operations (in dollars per share) 1.70 1.08
Income from Discontinued Operations (in dollars per share) 0 0.17
Net Income (in dollars per share) $ 1.70 $ 1.25